Bank of New York Mellon Corp Buys 26,510 Shares of Glaukos Co. (NYSE:GKOS)

Bank of New York Mellon Corp boosted its stake in Glaukos Co. (NYSE:GKOS) by 6.8% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 413,680 shares of the medical instruments supplier’s stock after buying an additional 26,510 shares during the period. Bank of New York Mellon Corp’s holdings in Glaukos were worth $48,959,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of GKOS. EFG Asset Management North America Corp. grew its holdings in shares of Glaukos by 0.5% in the 2nd quarter. EFG Asset Management North America Corp. now owns 27,205 shares of the medical instruments supplier’s stock worth $3,216,000 after purchasing an additional 128 shares during the last quarter. Louisiana State Employees Retirement System boosted its position in Glaukos by 4.5% in the second quarter. Louisiana State Employees Retirement System now owns 25,300 shares of the medical instruments supplier’s stock valued at $2,994,000 after buying an additional 1,100 shares in the last quarter. Caldwell Sutter Capital Inc. grew its stake in Glaukos by 162.6% during the second quarter. Caldwell Sutter Capital Inc. now owns 3,913 shares of the medical instruments supplier’s stock worth $463,000 after buying an additional 2,423 shares during the last quarter. Fifth Third Wealth Advisors LLC acquired a new stake in shares of Glaukos during the second quarter worth approximately $187,000. Finally, Raymond James & Associates raised its stake in shares of Glaukos by 23.2% in the second quarter. Raymond James & Associates now owns 13,017 shares of the medical instruments supplier’s stock valued at $1,541,000 after acquiring an additional 2,452 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors.

Insider Transactions at Glaukos

In other news, COO Joseph E. Gilliam sold 5,000 shares of the company’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $129.36, for a total value of $646,800.00. Following the completion of the sale, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at approximately $13,216,581.84. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Glaukos news, Director Aimee S. Weisner sold 25,000 shares of Glaukos stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the transaction, the director now directly owns 30,119 shares in the company, valued at $3,614,280. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Joseph E. Gilliam sold 5,000 shares of the business’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $129.36, for a total value of $646,800.00. Following the completion of the transaction, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at $13,216,581.84. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,000 shares of company stock worth $4,990,740. 6.40% of the stock is currently owned by company insiders.

Glaukos Stock Up 1.0 %

Shares of NYSE GKOS opened at $133.89 on Friday. Glaukos Co. has a 1 year low of $59.22 and a 1 year high of $136.36. The firm’s 50-day moving average is $122.24 and its 200-day moving average is $107.69. The company has a current ratio of 5.48, a quick ratio of 4.68 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $6.74 billion, a PE ratio of -46.49 and a beta of 1.05.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) EPS for the quarter, hitting analysts’ consensus estimates of ($0.52). The firm had revenue of $95.70 million during the quarter, compared to analyst estimates of $88.86 million. Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The business’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.55) EPS. Equities analysts expect that Glaukos Co. will post -2.25 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently commented on GKOS shares. Needham & Company LLC increased their price target on Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Citigroup lowered Glaukos from a “buy” rating to a “neutral” rating and raised their target price for the company from $130.00 to $132.00 in a research note on Wednesday, July 10th. StockNews.com downgraded shares of Glaukos from a “hold” rating to a “sell” rating in a research report on Friday. Jefferies Financial Group upgraded shares of Glaukos from a “hold” rating to a “buy” rating and raised their price objective for the company from $84.00 to $125.00 in a research report on Monday, May 6th. Finally, BTIG Research upped their target price on shares of Glaukos from $131.00 to $139.00 and gave the stock a “buy” rating in a research report on Wednesday. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Glaukos has an average rating of “Moderate Buy” and a consensus target price of $128.45.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.